Medicamen Biotech Limited (MEDICAMEQ.BO)
INR 562.7
(1.74%)
INR 562.7
(1.74%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -40.38 Million | -62.92 Million | 41.09 Million | 127.71 Million | 128.01 Million | 43 Million |
| Net Income | 109.31 Million | 147.28 Million | 148.97 Million | 121.29 Million | 132.91 Million | 120.25 Million |
| Depreciation & Amortization | 70.93 Million | 63.66 Million | 57.71 Million | 25.19 Million | 24.99 Million | 22.14 Million |
| Deferred income taxes | -6.35 Million | -13.83 Million | -7.79 Million | 1.19 Million | -2.5 Million | 7145.00 |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -211.42 Million | -287.76 Million | -178.2 Million | -25.9 Million | -36.37 Million | -112.91 Million |
| Other non-cash items | 203.87 Million | 22.02 Million | 12.65 Million | 9.1 Million | 2.48 Million | 129.95 Thousand |
| Investing Cash Flow | -62.86 Million | -58.8 Million | -84.72 Million | -178.12 Million | -372.91 Million | -147.56 Million |
| Investments in PPE | -62.86 Million | -66.01 Million | -86.08 Million | -179.65 Million | -376.1 Million | -156.81 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 7.24 Million | 7.2 Million | 1.35 Million | 1.53 Million | 3.19 Million | 9.24 Million |
| Financing Cash Flow | 43.32 Million | 291.27 Million | 42.97 Million | 58.38 Million | 190.62 Million | -36.89 Million |
| Debt repayment | -66.34 Million | -1.65 Million | -70.15 Million | -73.59 Million | -39.97 Million | -26.31 Million |
| Dividends payments | -12.65 Million | -12.65 Million | -12.21 Million | -6.1 Million | -14.7 Million | - |
| Common Stock Repurchased | - | -33.36 Million | - | -12.18 Million | 17.69 Million | - |
| Common Stock Issuance | 18.96 Million | 334.11 Million | - | 1.54 Million | 250.55 Million | - |
| Other Financing Activities | -29.33 Million | 4.83 Million | 125.34 Million | 148.72 Million | -25.41 Million | -10.58 Million |
| Accounts receivables | 99.98 Million | -20.34 Million | -106.76 Million | -25.89 Million | -65.87 Million | -49.47 Million |
| Accounts payables | -21.67 Million | 42.85 Million | 110.88 Million | -51.69 Million | 68.11 Million | 87.69 Million |
| Inventory | -143.17 Million | -180.47 Million | -218.05 Million | 117.53 Million | -16.97 Million | -10.26 Million |
| Other working capital | -146.56 Million | -129.79 Million | 35.72 Million | -65.84 Million | -21.64 Million | -140.88 Million |
| Cash at beginning of period | 25.92 Million | 38.24 Million | 38.9 Million | 30.92 Million | 85.19 Million | 226.64 Million |
| Cash at end of period | 147.85 Million | 207.78 Million | 38.24 Million | 38.9 Million | 30.92 Million | 85.19 Million |
| Capital Expenditure | -62.86 Million | -66.01 Million | -86.08 Million | -179.65 Million | -376.1 Million | -156.81 Million |
| Effect of forex changes on cash | - | -1000.00 | - | - | - | - |
| Net cash flow / Change in cash | 121.92 Million | 169.54 Million | -658 Thousand | 7.97 Million | -54.26 Million | -141.45 Million |
| Free Cash Flow | -103.25 Million | -128.93 Million | -44.99 Million | -51.94 Million | -248.09 Million | -113.8 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 13.51 Million | 21.27 Million | 109.31 Million | 20.29 Million | 15.13 Million | 41.77 Million |
| Depreciation & Amortization | - | - | 70.93 Million | 18.04 Million | 18.23 Million | 16.9 Million |
| Deferred income taxes | - | - | -6.35 Million | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | -211.42 Million | - | - | - |
| Other non-cash items | -13.51 Million | -21.27 Million | 203.87 Million | -20.29 Million | -15.13 Million | -41.77 Million |
| Investing Cash Flow | - | - | -62.86 Million | - | - | - |
| Investments in PPE | - | - | -62.86 Million | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 7.24 Million | - | - | - |
| Financing Cash Flow | - | - | 43.32 Million | - | - | - |
| Debt repayment | - | - | -66.34 Million | - | - | - |
| Dividends payments | - | - | -12.65 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 18.96 Million | - | - | - |
| Other Financing Activities | - | - | -29.33 Million | - | - | - |
| Accounts receivables | - | - | 99.98 Million | - | - | - |
| Accounts payables | - | - | -21.67 Million | - | - | - |
| Inventory | - | - | -143.17 Million | - | - | - |
| Other working capital | - | - | -146.56 Million | - | - | - |
| Cash at beginning of period | - | - | 25.92 Million | 134.28 Million | 111.99 Million | 25.92 Million |
| Cash at end of period | - | - | 147.85 Million | 170.38 Million | 134.28 Million | 41.77 Million |
| Capital Expenditure | - | - | -62.86 Million | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | 121.92 Million | 36.09 Million | 22.29 Million | 15.84 Million |
| Free Cash Flow | - | - | -103.25 Million | 36.09 Million | 22.29 Million | 41.77 Million |
3880
BHC
LEGN
STMEF
ALVAZ
688788